News and Press Releases
Jemperli®▼(dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer
Jemperli (dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer Following a...
Category: Drug Delivery, Other, Pharmaceutical
Posted: November 25, 2025
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
21 May 2025 -- Surrey, UK -- Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final draft guidance which recommends Hympavzi (marstacimab)...
Category: Drug Discovery, Other, Pharmaceutical
Posted: May 21, 2025
Carbon Minimal pressurised Metered Dose Inhalers (pMDIs) could save up to 619,000 tonnes of emissions each year, representing up to 7%-10% of NHS Net Zero targets
At a national level, seamless transitioning to a range of carbon minimal pMDIs could save between 415,000 and 619,000 tCO₂e annually, reducing carbon emissions to the equivalent financial value of...
Category: Drug Delivery, Manufacturing and Packing
Posted: March 10, 2025
NHS patients receive medicines manufactured by Octapharma using UK-donated plasma for the first time in almost 30 years
The sole manufacturer for the UK’s Plasma for Medicines (PfM) programme is supporting the Department of Health and Social Care, NHS England, and NHS Blood and Transplant to build resilience...
Category: Other, Pharmaceutical
Posted: March 6, 2025
Medicines manufacturing skills project uses Virtual Reality to help NHS reach net zero
Resilience, a UK government initiative, says its use of VR will reduce travel and waste 10 February 2025 – The recently launched government-funded medicines manufacturing skills project, Resilience, has said...
Category: Manufacturing and Packing
Posted: February 11, 2025
Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland
AGAMREE® is approved by MHRA for treating Duchenne muscular dystrophy (DMD) in patients 4 years of age and older in UK 14 January 2025 -- Pratteln, Switzerland -- Santhera Pharmaceuticals...
Category: Other, Pharmaceutical
Posted: January 14, 2025
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland
AbbVie’s SKYRIZI® (risankizumab) Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative Colitis
Risankizumab will be available on the NHS in Scotland for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to,...
Category: Clinical Trials, Pharmaceutical
Posted: January 13, 2025
Santhera Receives Positive Recommendation from NICE for AGAMREE (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
AGAMREE® has been recommended by NICE for treating Duchenne muscular dystrophy (DMD) in patients 4 years of age and older in England, Wales and Northern Ireland Santhera will be working...
Category: Drug Discovery, Other, Pharmaceutical
Posted: December 10, 2024
Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland
Scotland first in the UK to recommend a new treatment option for lung cancer, which could help lower the risk of cancer returning
7 October 2024 -- Scotland, UK -- the Scottish Medicines Consortium has recommended MSD's KEYTRUDA® (pembrolizumab) as monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma (NSCLC)...
Category: Other, Pharmaceutical
Posted: October 7, 2024
Major distribution centre opens to support health services in North West England
18 July 2024 – Nottingham, UK – A new NHS Supply Chain regional distribution centre that will support 115 NHS Trusts is now fully operational, providing a more resilient and...
Category: Logistics, Manufacturing and Packing
Posted: July 31, 2024
GSK’s Jemperli▼ (dostarlimab) is accepted for use within NHS Scotland, in line with its licence, in eligible endometrial cancer patients in first line setting
Clinicians in Scotland will now be able to use dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced...
Category: Pharmaceutical
Posted: April 8, 2024
Scottish Medicines Consortium (SMC) accepts Camzyos▼(mavacamten) for use on the NHS as an adjunct treatment option for adults with symptomatic obstructive hypertrophic cardiomyopathy
Mavacamten has been accepted for use within NHS Scotland for the treatment of symptomatic(New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy(HCM) in adult patients. HCM is...
Category: Pharmaceutical
Posted: April 8, 2024
ARC Uxbridge Sanderson Road New Denham Denham Buckinghamshire UB8 1DH
Scottish Medicines Consortium accepts Sotyktu(deucravacitinib) for NHS use in certain adults with moderate to severe plaque psoriasis
Deucravacitinib has been accepted by the Scottish Medicines Consortium (SMC) for use in Scotland for the treatment of adults with moderate to severe plaque psoriasis who are eligible for systemic...
Category: Pharmaceutical
Posted: December 11, 2023
ARC Uxbridge Sanderson Road New Denham Denham Buckinghamshire UB8 1DH
